People channel feed

For­get biosim­i­lars. Pe­ter Bach and Mark Trusheim be­lieve price con­trols are the bet­ter way to rein in bi­o­log­ics prices

7 years ago
Pharma

With $150M and a new NASH dis­cov­ery deal with Gilead, AI star Daphne Koller has set out to change the drug R&D world

7 years ago
Financing

In­flu­en­tial proxy firms kick back at ac­tivists’ de­mands for Brent Saun­ders to give up his chair­man’s ti­tle at Al­ler­gan

7 years ago

Road war­rior: Hal Bar­ron's glob­al R&D cru­sade at GSK comes with a hefty $800,000-plus trav­el bud­get

7 years ago

Two more Big Phar­ma CEOs en­joyed hefty rais­es in 2018, leav­ing the in­dus­try’s on­ly ma­jor league fe­male chief in firm con­trol of last place

7 years ago

Pe­ter Hecht re­cruits Bay­er/Shire vet An­dreas Busch for a top R&D post at his $175M biotech spin­out

7 years ago

Tapped as Kymab CEO, Si­mon Sturge jumps back in­to biotech pond as Dave Chiswell steps aside

7 years ago

Out­side re­view con­firms top Memo­r­i­al Sloan Ket­ter­ing ex­ec­u­tives flout­ed con­flicts-of-in­ter­est poli­cies — re­port

7 years ago

Al­ready miss­ing FDA's vo­cal com­mish? Scott Got­tlieb will keep chim­ing in on drug pric­ing in new role

7 years ago
Pharma

Biotech bil­lion­aire faces ac­cu­sa­tions of fraud for $1.3B 'catch-and-kil­l' can­cer drug deal

7 years ago

Ab­b­Vie share­hold­er joins the grow­ing ranks of crit­ics, call­ing for an in­de­pen­dent chair­man

7 years ago

Sure Hervé Hop­penot took a big cut in com­pen­sa­tion af­ter a pipeline dis­as­ter. But he still outscored the on­ly woman on the list

7 years ago

Af­ter a 33-year odyssey, Jef­frey Blue­stone grabs a ring­side seat to watch his drug teplizum­ab go back in­to the clin­ic

7 years ago

Jim Mel­lon's Ju­ve­nes­cence takes a chance on tiny up­start run by for­mer Pfiz­er ex­ec

7 years ago
Financing

Alex­ion chief reg­is­ters $16.5M in pay af­ter a sol­id year, with a rel­a­tive­ly low 74-to-1 ra­tio com­pared to a well paid staff

7 years ago

Al­ler­gan chief Brent Saun­ders bows to ac­tivists, but Ap­paloosa blasts back that it's all too lit­tle, too late

7 years ago
Deals

Af­ter land­ing a his­toric FDA OK, Al­ny­lam chief John Maraganore scores a big raise

7 years ago

Lit­tle Cona­tus' No­var­tis-part­nered liv­er drug suf­fers third straight de­feat, but CEO Men­to is still hold­ing out hope

7 years ago
R&D

$757M and 5 years lat­er, Cel­gene aban­doned a biotech part­ner, trig­ger­ing lay­offs

7 years ago
R&D

Found­ing For­ma CEO Steve Tre­gay fol­lows 61 staffers out the ex­it, re­placed by Genen­tech strat­e­gy vet

7 years ago

Is a new CEO in the cards at Sanofi as suc­ces­sion plan­ning heats up for top team?

7 years ago

Gilead CEO Mil­li­gan capped a rocky year — and his ca­reer — with the new #1 com­pen­sa­tion pack­age in the big leagues of bio­phar­ma

7 years ago

Des­per­ate­ly seek­ing a turn­around, be­lea­guered vet­er­an fund man­ag­er Wood­ford hits out at crit­ics, fake news

7 years ago

Ian Read bags $19.5 mil­lion, tak­ing a big pay cut for his swan song as Pfiz­er CEO and leav­ing the phar­ma gi­ant at a cross­roads

7 years ago
First page Previous page 80818283848586 Next page Last page
A service from the Financial Times